Intraoperative digital specimen mammography (IDSM) was equally accurate as SSM obtained in this study. Use of this new technology allows surgeons to quickly view specimen images which translate into shorter more efficient operations.
53 Background: A three dimensional bioabsorbable coiled tissue marker has been developed to facilitate targeting for radiation therapy post lumpectomy. Proposed advantages are a) clarified targeting of closest margins to the excised tumor, b) providing a three dimensional structure that allows fibrosis to add volume to contribute to cosmesis, c) aiding in re-excision localization. Our experience has demonstrated the array of clinical findings after placement, the imaging findings over time, and pathologic findings for early and late removal. Methods: Consecutive lumpectomy patients who were candidates for targeted radiation therapy were implanted with the 3-D bioabsorbable marker from May 2014 to June 2015. After informed consent, each of 36 patients were followed to gather clinical, imaging and pathologic findings. Standard breast cancer management decisions were made (NCCN). Patients requiring re-excision were examined for pathologic findings related to the device. Routine imaging with mammography and ultrasound were obtained at 6 and 12 months post lumpectomy. Results: The use of the spiral tissue marker with the fixed array of six titanium clips provided a predictable target for radiation treatments. As the tissue marker was sewn to the closest tumor bed, inadvertent dissection planes caused by oncoplastic techniques could be avoided. Clinically the lumpectomy site was firm/dense in 94% of patients at 3 months (n = 36), but in only 60% at one year (n = 21). Two patients who underwent re-excision for positive margins were guided by the 3-dimensional device. Two patients had removal at one month and at 12 months for reasons unrelated to the tissue marker. Histologic examination demonstrated typical foreign body reaction and organization (fig 1b). Mammography at one year demonstrated marker clips coalescing as the bioabsorbable device dissolves with maintenance of the volume of the cavity in 50% of patients(fig 1c). Cosmetic outcome has been good to excellent measured at 6 and 12 months. Conclusions: Clinical, radiologic and pathologic findings during use of a novel bioabsorbable 3-dimensional tissue marker were presented. A national registry to further define these attributes will soon be started.
Introduction: The appearance after breast surgery has become an important aspect of survivorship. The post lumpectomy/post radiation hollow surgical defect negatively impacts cosmesis and patient satisfaction. Oncoplastic procedures will mobilize surrounding tissues into the lumpectomy cavity but adds no volume to the breast. Use of a bioabsorbable 3-dimensional tissue implant (used for targeting radiation) has the additional benefit of adding volume to the breast and enhances the overall cosmetic appearance. Our experience over 3 years provides serial mammograms from which we may objectively categorize cosmetic contour. We report on our 2 and 3 year serial images of our treated patients compared with baseline. Methods: Between May 2014 and June 2018, during lumpectomy for breast cancer we implanted a 3-D tissue implant marker in 170 patients, often combined with oncoplastic reconstruction and followed by radiation treatment. For long term follow-up we had 37 patients with serial mammograms at 2 or 3 years to assess cosmesis. All patients had interviews, physical exams, and serial mammograms to evaluate their cosmetic appearance. Both physician and patient graded their appearance. We also objectively measured and compared the pre-treatment mammogram and the 2-year and 3-year, post-treatment mammogram for symmetry and size using each breast as its own control. Using the post-treatment mammograms, we compared the relative anterior-posterior (depth) measurement of the quadrant bearing the implant as well as the non-cancer quadrant to the similar locations of the pre-treatment mammogram. Both mammogram positioning and radiation effects would balance. We compared the relative change from baseline in the non-cancer portion of the breast to the change from baseline in the cancer portion of the breast as a percent difference from baseline. Results: Patients were treated with lumpectomy, oncoplastic reconstruction, and placement of a 3-D tissue implant. Three implants were removed due to positive margins. No implants were removed for any other reason. There have been no local recurrences. Overall, radiation oncologists felt the 3-D implant was useful for treatment planning in 85% of patients. Of the 37 consecutive patients who have completed an average of 27.8 months of follow-up, cosmesis was rated as excellent/good by clinicians (96%) and patients (94%). Mammograms taken at 2-3 years were compared with initial images. Whole-breast radiation effect varied among patients. Some had significant shrinkage while others had none. These changes were equal in the non-cancer post-radiation quadrants (86.2% vs 87%) demonstrating maintenance of normal breast contour. Our use of the 3-D implant and oncoplastic tissue advancement maintained the pre-operative contour of the breast after lumpectomy with radiation. Conclusions: Breast cancer surgery and radiation is often complicated by poor cosmesis with retraction and volume loss. Using a combination of oncoplastic surgery combined with a 3-D tissue implant, we found the forward projection and contour of the breast at the lumpectomy site was preserved and patient satisfaction was good to excellent. Further investigation of the long-term cosmetic effects of breast cancer surgery should be encouraged. Citation Format: Kaufman CS, Hall W, Behrndt VS, Wolgamot GM, Zacharias K, Rogers A, Smith A, Hill LM, Schnell N. Enhance post-lumpectomy breast contour using oncoplastic surgery (OPS) plus a bioabsorbable 3-D tissue implant [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-16-02.
Background: Breast conservation surgery (BCS) may preserve the breast but many women have less than optimal cosmetic outcomes. Increasingly, this has been addressed by the use of oncoplastic reconstruction.Now, targeting radiation treatment for boost or partial breast irradiation (PBI) using the seroma has become more difficult due to the adjacent tissue rearrangement and resultant “benign” seromas. Since the radiation dose generated increases by the third power of the radius (r3), there is a need to accurately focus radiation therapy to avoid chronic radiation side effects.We have used a 3-dimensional bioabsorbable tissue marker to accurately target the tumor bed while excluding inadvertent seromas caused by oncoplastic procedures. We report on tissue marker implantation on 61 consecutive breast conservation patients in regards to targeting, impact on cosmesis, imaging followup, ease of re-excision, as well as side effects and patient satisfaction. METHODS: Consecutive lumpectomy patients who were candidates for targeted radiation therapy were considered for implantation with the 3-D bioabsorbable marker from May 2014 to June 2016. The tissue marker has a fixed array of 6 titanium clips and was sutured to the site of the excised breast cancer during lumpectomy.The framework of the implant resorbs slowly over time, while the clips remain permanently. All patients had oncoplastic reconstruction with total implant coverage. The marker was utilized for boost or partial breast irradiation (PBI) planning or treatment targeting. Data includes patient demographics, breast size, tumor characteristics, surgical and radiotherapy techniques, follow-up imaging, cosmesis and patient satisfaction. Results:Data on 61 patients with median follow-up 12.7 months was analyzed (range 1.5–25.5). Median age was 62.4 years (range 33-74), 5 of women were postmenopausal and 15% had comorbidities. Cancer histology was in-situ (13%), invasive ductal (84%), invasive lobular (3%) of sizes T0 (13%), T1 (59%), T2 (25%), T3-4 (3%). Laterality and tumor location within the breast were typical. Re-excisions occurred in 11% of patients. No infections occurred in the postoperative period. One infection occurred with chemotherapy and another with repeated aspirations of oncoplastic area.No device was removed for infection, misplacement or patient-generated concerns. No cancer recurrences have been reported. Size of device used reflected size of the tumor; 2X2cm (44%), 2X3cm (34%) and 3X3cm (20%). The device was utilized by radiation oncologists for boost or PBI planning and treatment. Data on ease of setup and boost planning is being collected. Mammography at one year demonstrated marker clips coalescing as the bioabsorbable device dissolves. Evaluation of cosmetic appearance has shown good to excellent cosmesis as judged separately by both physicians and patients (92% and 94%). Conclusions: Initial experience with 61 patients implanted with a novel 3-D absorbable device prospectively followed for an average of 12 months can be used in an array of breast cancer patients without device specific morbidity. Good to excellent cosmesis may be related to the addition of volume to the lumpectomy bed not seen with rearrangement of existing tissues. Citation Format: Kaufman CS, Hall W, Behrndt V, Wolgamot G, Hill L, Zacharias K, Rogers A, Nix S, Schnell N. Use of a 3-D bioabsorbable tissue marker in 61 patients over two years [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-13-20.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.